Abstract:Topic: 17. Hodgkin lymphoma - Clinical Background: Although the promising benefit of PD-1 inhibitors for relapsed/refractory Hodgkin’s lymphoma (R/R HL) has been shown by several large clinical trials, there remains a paucity of studies describing outcomes and prognosis of patients with immunotherapy in a real-world setting. Meanwhile, there are still some patients not responded or early relapsed to new agents, thus raising the focus on prognostic factors in new era. Aims: We evaluated the real-world benefit and conducted a prognostic analysis of two PD-1 inhibitors developed in China (Sintilimab or Tislelizumab) for R/R HL patients, aiming to establish a new risk model for better immune risk-adapted therapeutic strategy. We hope our study could provide supplementary information to global related studies, as well as to be a reference for Asian working groups. Methods: We present a retrospective analysis of patients with R/R cHL who had failed ≥2 prior lines of therapies and received sintilimab or tislelizumab monotherapy at 3 medical centers from January 2020 to September 2022. Results: A total of 74 patients were reviewed. The median age was 38 years (range, 14-85 years). Patients had a median of 3 (2–6) previous lines of therapy. The ORR and CRR for the whole cohort were 78.3% and 52.7%, respectively. The median duration of follow-up was 22 (4–36) months. Overall, four patients (5.4%) died of disease progression during follow-up. The 2-y estimated PFS, DOR and OS rate was 43.3%, 45.1% and 94.1%, respectively. The median PFS and DOR was 22.1 and 23.5 months while the median OS has not reached. Ann Arbor IV (HR=3.547, p=0.044, 95% CI: 1.033–10.177) and refractoriness to most recent prior therapy (HR=4.002, p=0.031, 95% CI: 1.136–11.099) remained as independent prognostic factors for PFS based on multivariate analysis. Early response evaluation using either CT or PET/CT is predictive of long-term outcome in patients with R/R HL treated with anti-PD-1 mAbs. Significant differences were observed in PFS between patients who achieved the early C(M)R versus non-C(M)R (estimated 2y PFS: 71.9% vs. 32.3%, p=0.004). A new risk model incorporating traditional risk factors and early imaging assessment stratified patients into 3 classes: favorable group with early CR (n=21, 28.4%), unfavorable group or early non-CR (n=29, 39.2%), and unfavorable group with early non-CR (n=24, 32.4%), with 1-y PFS of 100.0%, 81.3%, and 37.5%, respectively (p=0.0001), as it was 75.0% vs. 43.3% vs. 15.0%, regarding estimated 2-y PFS (p< 0.0001) (Figure).Summary/Conclusion: Our findings suggest that PD-1 targeted immunotherapy with sintilimab or tislelizumab given in a real-world clinical setting was associated with efficacy similar to those reported by published trials. In new era of immunotherapy, several traditional risk factors retained certain impact on prognosis. Early imaging assessment appears to yield significantly prognostic value for R/R HL patients treated with anti-PD-1mAbs. The novel risk assessment model showed potential as a more powerful prognostic tool by identifying patients with significantly distinct outcomes, which warrants further validations and serves as a basis for future immune risk-adapted strategies. Keywords: Immunotherapy, Risk-adapted, Hodgkin’s lymphoma, relapsed/refractory

Whole slide imaging of tumour microenvironment in classical Hodgkin’s lymphoma: development of a clinical prediction model based on programmed death-ligand 1 and tumorous Reed-Sternberg cells

Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD

The Prognostic and Clinicopathological Significance of PD-L1 Expression in Patients with Diffuse Large B-cell Lymphoma: a Meta-Analysis

Decreased peripheral blood lymphocyte-monocyte ratio and platelet-monocyte ratio and the Peripheral Blood Score model predict poor survival in peripheral T-cell lymphoma patients

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

Characterization of PD-L1 Protein Expression and CD8+ Tumor-Infiltrating Lymphocyte Density, and Their Associations with Clinical Outcome in Small-Cell Lung Cancer.

Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell Lymphoma

Combined Identification of Novel Markers for Diagnosis and Prognostic of Classic Hodgkin Lymphoma.

P1074: PROGNOSIS ANALYSIS AND A NEW RISK MODEL FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED BY ANTI-PD-1: A REAL-WORLD MULTICENTER RETROSPECTIVE STUDY OF PATIENTS IN CHINA

Prognostic Role of the Expression of Latent-Membrane Protein 1 of Epstein-Barr Virus in Classical Hodgkin Lymphoma

Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma

Prognostic Impact of the Immunoscore Based on Whole-Slide Image Analysis of CD3+ Tumor-Infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma

Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma

Combination of FDG PET/CT Radiomics and Clinical Parameters for Outcome Prediction in Patients with Hodgkin’s Lymphoma

Author Response for "combined Tumor‐associated Macrophages Biomarker Predicting Extremely Poor Outcome of Patients with Primary Central Nervous System Lymphoma"

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium

Decreased CD11c‐positive dendritic cells in the tumor microenvironment predict double‐hit/triple‐hit genotype and survival in diffuse large B‐cell lymphoma

Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD

FOXP3+/CD68+ ratio within the tumor microenvironment may serve as a potential prognostic factor in classical Hodgkin lymphoma

Combined tumor‐associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma

Prognostic Value Of Tumor Infiltrating Lymphocytes Combined With Pd-L1 Expression For Patients With Solitary Colorectal Cancer Liver Metastasis